SecBot SecBot
PRESS-RELEASE ·Filed Aug 6, 2026

CGON

CG Oncology Inc.
BEARISH
Impact 7/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss and ATM offering create near-term bearish pressure. Monitor for PIVOT-006 topline data as a potential catalyst; a positive readout could offset dilution concerns. The BLA submission timeline (Q4 2026) is a key milestone. The stock may trade on pipeline updates rather than quarterly financials, but the capital raise signals significant cash needs before commercialization.

DirectionBearish
Confidencehigh
Horizonweeks

cretostimogene

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
BLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.
Next catalyst
None dated

What to watchWatch for BLA submission completion in Q4 2026, this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$74.85
T+0 close · Aug 6, 2026 · via day close
Latest settled
−15.20%
T+60 · $63.47
Vs SPY
−13.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $74.85entry
  2. T+1 · 3mo ago +0.33%α −0.28% · $75.10
  3. T+5 · 3mo ago −0.19%α −1.40% · $74.71
  4. T+20 · 3mo ago −0.69%α −1.29% · $74.33
  5. T+60 · 18d ago −15.20%α −13.78% · $63.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology reported Q2 2026 EPS of -$0.90, significantly wider than the consensus estimate of -$0.64 (a 40.6% miss), with revenue of $1.157M (vs consensus $363K, a 218.7% beat). The net loss widened to $79.1M from $41.4M a year ago, driven by a 74% increase in R&D spend and a 66% increase in G&A costs. The stock is likely to be pressured by the EPS miss and the concurrent $500M ATM equity offering, which signals aggressive funding needs and potential dilution, partially offset by the revenue beat and positive pipeline milestones (PIVOT-006 topline data expected soon, BLA submission in Q4 2026). The company has $1.0B in cash, sufficient through 2029, but the massive capital raise overshadows the near-term outlook.

Key Financial Metrics

EPS
−$0.90
est −$0.64 · -40.6%
Revenue
$1.2M
est $363.0K · +218.7%
Rating
strong miss

Key Facts

  • Q2 2026 EPS of -$0.90 missed consensus of -$0.64 by 40.6%
  • Q2 2026 revenue of $1.157M beat consensus of $363K by 218.7%
  • Net loss widened to $79.1M from $41.4M YoY, driven by higher R&D ($54.7M vs $31.3M) and G&A ($29.0M vs $17.4M) expenses
  • Cash, cash equivalents and marketable securities at $1.0B, down from $1.1B in Q1 2026; sufficient through 2029
  • Concurrent $500M ATM equity offering upsized to $1.05B total, representing potential ~7.8% dilution at current prices
  • PIVOT-006 Phase 3 topline data for intermediate-risk NMIBC anticipated near-term; BLA submission for HR BCG-unresponsive NMIBC expected Q4 2026
  • BOND-003 Cohort C results published in The Lancet Oncology in July 2026
  • Delaware Superior Court upheld jury verdict in favor of CG Oncology in ANI litigation

Financial Impact

Net loss of $79.1M in Q2 2026, EPS miss of $0.26 vs consensus, and a $500M ATM offering creating dilution risk

epsnet lossdilutioncash burn

Risk Factors

  • Dilution from the $500M ATM offering could pressure stock price
  • Widening net loss and increasing cash burn rate may concern investors
  • Clinical trial risks: PIVOT-006 topline data could disappoint
  • Regulatory risk: BLA submission and potential FDA approval for cretostimogene are uncertain
  • Litigation overhang from ANI dispute, though recent court ruling was favorable

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3340256

Track record

25 reports on CGON

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Viewing Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026